Patents by Inventor HeeJi Lim

HeeJi Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME
    Publication number: 20240316184
    Abstract: The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.
    Type: Application
    Filed: July 19, 2022
    Publication date: September 26, 2024
    Applicant: BioApplications Inc.
    Inventors: Eun-Ju SOHN, Bo-Hwa CHOI, Hyangju KANG, Kyungmin MIN, Minhee PARK, Nam Hyung KIM, Daniel KIM, Yoo-Kyoung LEE, Byung-Chul KIM, Heeji LIM, Sundong JANG, Kwangwook KIM, Soo Ji KIM, Dokeun KIM, You-Jin KIM, Jung-Ah LEE, Woo-Jung PARK
  • Recombinant antigen derived from Zika virus E protein and use thereof
    Patent number: 11291714
    Abstract: The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: April 5, 2022
    Assignee: Korea Center for Disease Control and Prevention
    Inventors: You-Jin Kim, Hyun Ju In, HeeJi Lim, Sun-Dong Jang, Jung-Sik Yoo, Gyung Tae Chung
  • Recombinant Antigen Derived From Zika Virus E Protein And Use Thereof
    Publication number: 20200230227
    Abstract: The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.
    Type: Application
    Filed: December 10, 2019
    Publication date: July 23, 2020
    Applicant: Korea Center For Disease Control And Prevention
    Inventors: You-Jin Kim, Hyun Ju In, HeeJi Lim, Sun-Dong Jang, Jung-Sik Yoo, Gyung Tae Chung